Skip to content

Press Releases and Events

Press Release

Intra-Cellular Therapies Inc.
Apr 16, 2019
<< Back

Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard

NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, mourns the passing of our co-founder, Dr. Paul Greengard, a neuroscientist and Nobel Laureate whose pioneering research revolutionized our understanding of the biochemistry of the brain. Dr. Greengard’s Nobel prize-winning work in intracellular signaling was the foundation of the company’s formation in 2002.

“We are deeply saddened by the news of Paul’s passing. He has left an incredible mark on the world through his breakthrough contributions to neuroscience. We will always remember his kindness and humanity that made him a wonderful colleague and friend to many,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “We are honored to continue Paul’s legacy through our commitment to science and discovering new medicines for people living with neuropsychiatric and neurodegenerative diseases.”

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders.  Lumateperone is under review by the FDA for the treatment of schizophrenia and is in Phase 3 clinical development for the treatment of bipolar depression. Intra-Cellular Therapies is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson's disease and for the treatment of heart failure.


Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D. 
Vice President, Corporate Communications and Investor Relations

Intra-Cellular Therapies logo

Source: Intra-Cellular Therapies Inc.